A Prototype Neurotoxicological Database

描述（由申请人提供）：本NIH SBIR第二阶段拨款申请的目标是扩展和验证在第一阶段SBIR拨款期间构建的试点体外神经毒性数据库。毒性数据库将用于协助评价可用于人类治疗或通过使用对人类构成重大暴露潜力的新化合物的安全特性。在商业上，该数据库将由NOVASCREEN生物科学公司提供给制药、化学、农业和生物技术行业，以降低成本并简化其毒性测试要求。第二阶段的范围将是对第一阶段中使用的一组化合物进行进一步的体外毒性测试，并在两种神经来源的细胞系中筛选另外800种新化合物。该测试将包括测量细胞生长、代谢、呼吸、活力和凋亡的分析。来自动物和人类体内毒性测试标准化合物文献的注释以及NOVASCREEN自己专有的受体筛选数据库（RSM）的分析数据将被纳入该毒性数据库。

DESCRIPTION (provided by applicant): The goal of this NIH SBIR Phase II Grant Application is to expand and validate the pilot in vitro neurotoxicity database that was constructed during a Phase I SBIR Grant. The toxicity database will be used to aid in evaluating the safety characteristics of new chemical compounds that may be therapeutically administered to humans or that pose significant exposure potential to human populations through their use. Commercially, this database will be offered by NOVASCREEN Biosciences Corp. to the pharmaceutical, chemical, agricultural and biotech industries to reduce costs and streamline their toxicity testing requirements. The scope of this Phase II will be further in vitro toxicity testing of a select group of compounds used in Phase I and the screening of an additional 800 new compounds in two cell lines that are of neural origins. This testing will include assays that measure cellular growth, metabolism, respiration, viability and apoptosis. Annotations derived from the literature on animal and human in vivo toxicity testing standard compounds as well as assay data from NOVASCREEN's own proprietary receptor screening database (RSM) will be incorporated into this toxicity database.